Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

Table 4 Association between genetic variants and erythropoiesis stimulating agents (ESA) or colony stimulating factor (CSF) use

4A: Significant correlations with ESA use
	All patients	Patients with ESA use	Patients without ESA use	Unadjusted OR (95%CI)	*p-value	Adjusted OR (95% CI)	**Corrected p value
	N = 290 (%)	N = 70 (24.2%)	N = 219 (75.8%)	Unadjusted OR (95%CI)	*p-value	Adjusted OR (95% CI)	**Corrected p value
ABCC1 rs2074087	GG 215 (74.4)	46 (65.7)	169 (77.2)	1.78 (1.03- 3.08)	0.054	2.09 (1.18 - 3.68)	0.011
	GC 69 (23.9)	22 (31.4)	47 (21.5)
	CC 5 (1.7)	2 (2.8)	3 (1.4)
4B: Significant correlations with CSF use
	All patients	Patients with CSF use	Patients without CSF use	Unadjusted OR	*p-value	Adjusted OR	**Corrected p value
	N = 290 (%)	N = 62 (21.4%)	N = 228 (78.6%)	(95%CI)	*p-value	(95% CI)	**Corrected p value
ABCC2 rs2073337	AA 101 (34.8)	27 (43.5)	74 (32.5)	0.61 (0.39- 0.96)	0.031	0.60 (0.37-0.99)	0.039
	AG 148 (51.0)	31 (50.0)	117 (51.3)
	GG 41 (14.1)	4 (6.5)	37 (16.2)
GSTP1 rs1695	AA 121 (41.7)	33 (53.2)	88 (38.6)	0.54 (0.34; 0.86)	0.010	0.55 (0.33-0.90)	0.017
	AG 137 (47.2)	27 (43.5)	110 (48.2)
	GG 32 (11.0)	2 (3.2)	30 (13.2)
ERCC2 Rs1799793	GG 136 (48.2)	21 (33.9)	115 (50.4)	0.67 (0.45- 1.00)	0.048	0.63 (0.41-0.98)	0.042
	GA 111 (39.4)	30 (48.4)	81 (35.5)
	AA 35 (12.4)	9 (14.5)	26 (11.4)

OR: Odds Ratio using wild type as reference category. *Uncorrected p values were calculated using binary logistic regression for the need for ESA/CSF use without correction for covariates. Per-allele ORs and 95% CIs are shown. There were missing genotypes for rs2074087 (n = 1), rs1799793 (n = 8). **Corrected p values were obtained using a logistic regression for the need for ESA/CSF use while including the following covariates: genetic variants, age, BMI, dosage of carboplatin (AUC) and number of administered cycles.

ISSN: 2050-6511